Technology Transfer from the Weizmann Institute of Science
from our pipeline to your bottom line
Amir Naiberg, CEO
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
Yeda’s Business Club- June 2013
Science for the Benefit of
Society
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w.YedaRnD.com
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w.YedaRnD.com
April 2013
Merieux announces:
a two years collaboration with Prof. Ada Yonath.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w.YedaRnD.com
May 2013
Helio Focus announced that it signed a second strategic
agreement with China Guodian Corporation, one of
China’s largest power generation companies. The first stage of
the agreement calls for HelioFocus to plan and develop a
power boosting capability for Guodian’s 15MW – 40MW coal
powered facility to be located in China.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w.YedaRnD.com
September 2013
Micure Therapeutics was established.
The company develops drugs and diagnostics tools for the
treatment of depression and ALS. The technology was developed
by Profs. Alon Chen and Eran Hornstein.
Brainsway Gets FDA Approval Of IDE For Multi-Center
Smoking Cessation Study 12
JERUSALEM, Sept. 11, 2013-Brainsway Ltd. (BRIN.TA) is pleased
to announce that the U.S. Food and Drug Administration (“FDA”)
has approved an IDE (“Investigational Device Exemption”) that
allows the Company to begin implementing a double-blind, multicenter study to assess the efficacy of the its Deep TMS device in
inducing smoking cessation using a specialized coil developed for
this purpose.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w.YedaRnD.com
October 2013
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
Cont’d
Yeda and Osage University Partners, a venture
capital fund that invests exclusively in startups
that are commercializing university research, signed a
collaboration agreement.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
November 2013
Jianghua Group (JH), leading Chinese environmental
solution provider, took a license to two technologies for treating
contaminated water, developed by Prof. Brain Berkowitz.
SynVaccine was established in the Rad Biomed incubator.
The company develops a new safe and effective synthetic
vaccines, based on the work of Prof. Ehud Shapira.
Merck Serono and Kadimastem Sign Memorandum of
Understanding (MOU) on Drug Screening and Discovery
for Neurodegenerative Diseases.
November 4. 2013 (Nes Ziona. Israel and Darmstadt. Germany) Merck Serono, a leading
global pharmaceutical company, and Kadimastem, a developer of human pluripotent stem cellbased drug screening and therapeutic solutions, announced today the digning of an MOU
aimed at advancing the two companies’ current stem cell-based drug screening collaboration
which was initiated in April 2012.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
Cont’d
Yeda and BASF will collaborate in the development of
novel materials and catalytic processes.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
December 2013
Merck Millipore and Yeda sign a nonexclusive agreement
for the development marketing and sale of a novel kit for the
creation of novel naïve stem cells, developed by Prof. Jacob Hanna.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w.YedaRnD.com
January 2014
XTL Bio receives a license to develop a peptide, invited by
Prof. Edna Mozes, for the treatment of Lupus.
Merck Serono started collaboration with Prof. Idit Shahr for the
research and development of new therapies for the treatment of Lukmia.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
February 2014
Raptor Announces Clinical Results With RP103 in Huntington’s
Disease 2/3 Trial
18 Month Clinical Results Showed Significantly Slower Progression of Total
Motor Score in RP103 Treated Patients Without Tetrabenazine.
NOVATO, Calif., Feb.20,2014 (GLOBE NEWSWIRE) Raptor Pharmaceutical Corp. (Nasdaq:RPTP)
today announced top line results from a planned 18 month analysis of an ongoing 3 year Phase
2/3 clinical trail of RP103 (delayed-relese cysteamine) for the potential treatment of Huntington’s
disease (HD) in collaboration with the Centre Hospiaier Universitaire d’Angers (CHU d’Angers ). A
total of 96 patients with HD
Yeda and Merck Group (chemistry) announced 2 collaborations relating to
research and development of novel chemical compounds.
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
Cont’d.
CO2 To Fuel Technology - Stage 2 - Efficiency Proven
Mar. 12, 2014
NCF stage 2 testing further proves its technology, increasing
dissociation rate of CO2 to 800 times original laboratory tests, a
fourfold increase from Stage 1 testing announced in January |
NCF continuous tests now running for over 100hrs, proving
technology stability | NCF currently converting ~15kg CO2 into
~10kg of CO and 5kg oxygen (O2) per day
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
April 2014
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
May 2014
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om
www.YedaRnD.com
Thank you
Yeda Research & Development Co. Ltd.
Technology Transfer from the Weizmann Institute of Science
w w w .Yeda R n D .c om